Showing results (91-100 of 101) with videos related to
Sort By:
Pageof 11
Proceedings of the National Academy of Sciences of the United States of America|August 16, 2023
Structural insights into the interaction of three Y-shaped ligands with PI3KαQingtong Zhou, Xiao Liu, Dario Neri, et al.Genome Research|July 19, 2005
Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysisJosephine N Harada, Kristen E Bower, Anthony P Orth, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|November 20, 2015
Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator ComplexSheena M Saayman, Daniel C Lazar, Tristan A Scott, et al.Cancer Cell|April 17, 2014
MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancerNicola Valeri, Chiara Braconi, Pierluigi Gasparini, et al.Journal of Proteomics|July 22, 2015
ProteinInferencer: Confident protein identification and multiple experiment comparison for large scale proteomics projectsYaoyang Zhang, Tao Xu, Bing Shan, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 26, 2020
A Single-Stranded DNA-Encoded Chemical Library Based on a Stereoisomeric Scaffold Enables Ligand Discovery by Modular Assembly of Building BlocksGabriele Bassi, Nicholas Favalli, Miriam Vuk, et al.Molecular Therapy. Nucleic Acids|September 17, 2018
Comprehensive RNA-Sequencing Analysis in Serum and Muscle Reveals Novel Small RNA Signatures with Biomarker Potential for DMDAnna M L Coenen-Stass, Helena Sork, Sole Gatto, et al.Nature Chemistry|April 9, 2021
Stereo- and regiodefined DNA-encoded chemical libraries enable efficient tumour-targeting applicationsNicholas Favalli, Gabriele Bassi, Christian Pellegrino, et al.Molecular Cancer Therapeutics|July 14, 2011
PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activityJing Yuan, Pramod P Mehta, Min-Jean Yin, et al.Proceedings of the National Academy of Sciences of the United States of America|February 16, 2010
Disruption of angiogenesis and tumor growth with an orally active drug that stabilizes the inactive state of PDGFRbeta/B-RAFEric A Murphy, David J Shields, Konstantin Stoletov, et al.Pageof 11